Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for H3K27M-mutant Diffuse Midline Glioma (DMG)

NCT04196413 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT04196413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04196413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for H3K27M-mutant Diffuse Midline Glioma (DMG)
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Recruiting
Start date
June 4, 2020
Completion date
July 31, 2043
Enrollment
97 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma of brainstem, glioma of spinal cord